Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis reports ‘encouraging’ TroVax results

Sanofi-Aventis reports ‘encouraging’ TroVax results

3rd June 2008

Sanofi-Aventis and Oxford Biomedica have announced encouraging phase II trial results for TroVax in metastatic renal cancer during their presentations at the annual meeting of the American Society of Clinical Oncology.

A therapeutic cancer vaccine, TroVax is being developed by Oxfod BioMedica in collaboration with Sanofi-Aventis.

In a range of studies with different patient cohorts, TroVax was found to be well tolerated and generated a robust and consistent immune response to the tumour antigen 5T4, with encouraging levels of clinical benefit seen relative to historical controls.

There were no serious adverse events related to TroVax, with the most common side effect being a low-grade irritation at the site of injection.

An ongoing phase III Trist study of the compound in patients with locally advanced or metastatic clear cell renal carcinoma is due to be completed in the first half of 2009.

Dr Mike McDonald, chief medical officer of Oxford BioMedica, said: “With our partner, Sanofi-Aventis, we continue to be encouraged by the phase II results of TroVax.

“These updated analyses of three trials in metastatic renal cancer further support the mechanistic rationale that the immune response induced by TroVax has potential for clinical use in this setting.”

He added that the results also give key immunogenicity and safety data for the drug when administered together with two standard therapies for metastatic renal cancer.

Sanofi-Aventis entered into a global licensing agreement with Oxford BioMedical for the development and commercialisation of TroVax in March 2007.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.